在担任联邦参议员的12年间,我始终致力于维护美国在全球生物技术领域的主导地位。我之所以坚持推动这项工作,不仅因为行业领先优势能挽救美国人生命、拉动经济增长,更因为这对国家安全至关重要。
当美国企业在全球生物技术领域保持领先地位时,我们便能迅速应对突发公共卫生事件,而非受制于外部对手。我始终深感自豪的是,在担任美国国立卫生研究院监管小组委员会主席期间,我与两党同僚携手合作,推动该院经费增长近50%,加快科研步伐。这笔投入在新冠疫情期间收获成效:特朗普发起的“曲速行动”正是依托美国国立卫生研究院的前期科研项目,助力终结疫情,挽救无数美国人的生命。
正因如此,我对美国财政部一项可能适得其反的新提案感到担忧。该提案拟限制美国企业在华生物技术投资。
该提案虽以维护国家安全为宗旨,但从具体条文来看,其适用范围过于宽泛,对美国生物技术企业的冲击可能远超对中国企业的影响。
该提案将阻碍美国企业高效、快速推进突破性新药的研发进程,不仅可能损害美国患者的利益,更将危及国家安全。
美国制药企业常通过收购、合资以及其他合作模式,将海外前景可观的研发成果纳入自身研发管线。中国企业贡献的全球创新候选药物越来越多,这类合作的战略价值也日益凸显。
依托此类合作,美国患者将获得更多参与临床试验的机会,有望获得救命药物;美国企业亦能更全面地掌握新药研发、生产方式与布局,保障药品供应稳定。
此类合作不仅不会使美国受制于中国,反而将进一步巩固美国企业在全球医药领域的领先地位,并强化中国在药品供应环节对美国的依赖。2025年,美国对华医药贸易顺差达37亿美元。
10月下旬,美国财政部提议扩大《全面对外投资国家安全法案》的适用范围,该法案原旨在限制美国对中国战略敏感行业的投资,此次拟将生物技术产业整体纳入监管。此举将大幅限制美国企业投资、收购中国生物科技公司,或与其开展合作。
这种“一刀切”式的限制措施,更可能削弱美国自身实力,而非遏制中国。若美国企业被禁止与中国生物科技企业开展合作,中方企业并不会因此终止前景可观的研发项目。相反,它们将转而寻求与美国企业的国际竞争对手开展合作,或自主构建覆盖研发、生产及商业化环节的完整体系,从而摆脱对美合作伙伴的依赖。
长此以往,美国可能逐步丧失对下一代创新药物研发与供应链的掌控。患者等待前沿疗法的周期会拉长,参与临床试验的机会也会变少。
未来,美国获得创新药物更加依赖境外企业,恐构成严重国家安全隐患。
财政部官员明智的做法是收紧提案适用范围,只针对确实存在安全风险的生物技术交易——例如涉及生物武器技术的协议,而非一刀切地禁止常规科研合作。
财政部还需明确哪些合作模式属于禁令范畴。尽管提案本意允许常规授权许可协议,但条文表述宽泛,即便采用通用许可条款的合作,也有可能被认定为违规合资项目。这种政策不确定性,会迫使企业放弃有利的合作。
与此同时,政策制定者更应重视增强美国自身的科研实力:持续加大联邦科研投入、完善知识产权体系、保护科研机构免受外部干扰,并扩大本土研发与生产产能。
特朗普政府对中方发展目标保持警惕,但美国不能靠隔绝海外前沿科研成果,来维持自身在生物技术领域的领先地位。
唯有精准管控真正的安全风险,同时维护富有成效的研究伙伴关系,才能确保美国患者持续受益于全球最具潜力的医学突破。(财富中文网)
罗伊·布伦特1997年至2011年担任美国众议员,2011年至2023年出任参议员,曾任参议院情报特别委员会委员。他现任HB Strategies旗下领导力战略咨询服务集团主席,为制药和生物技术行业客户提供咨询,部分客户或受拟议中的《全面对外投资国家安全法案》相关规则影响。此外,他还担任Tenet Healthcare和Danforth Plant Science Center董事。
Fortune.com上发表的评论文章中表达的观点,仅代表作者本人的观点,不代表《财富》杂志的观点和立场。
译者:中慧言-王芳
在担任联邦参议员的12年间,我始终致力于维护美国在全球生物技术领域的主导地位。我之所以坚持推动这项工作,不仅因为行业领先优势能挽救美国人生命、拉动经济增长,更因为这对国家安全至关重要。
当美国企业在全球生物技术领域保持领先地位时,我们便能迅速应对突发公共卫生事件,而非受制于外部对手。我始终深感自豪的是,在担任美国国立卫生研究院监管小组委员会主席期间,我与两党同僚携手合作,推动该院经费增长近50%,加快科研步伐。这笔投入在新冠疫情期间收获成效:特朗普发起的“曲速行动”正是依托美国国立卫生研究院的前期科研项目,助力终结疫情,挽救无数美国人的生命。
正因如此,我对美国财政部一项可能适得其反的新提案感到担忧。该提案拟限制美国企业在华生物技术投资。
该提案虽以维护国家安全为宗旨,但从具体条文来看,其适用范围过于宽泛,对美国生物技术企业的冲击可能远超对中国企业的影响。
该提案将阻碍美国企业高效、快速推进突破性新药的研发进程,不仅可能损害美国患者的利益,更将危及国家安全。
美国制药企业常通过收购、合资以及其他合作模式,将海外前景可观的研发成果纳入自身研发管线。中国企业贡献的全球创新候选药物越来越多,这类合作的战略价值也日益凸显。
依托此类合作,美国患者将获得更多参与临床试验的机会,有望获得救命药物;美国企业亦能更全面地掌握新药研发、生产方式与布局,保障药品供应稳定。
此类合作不仅不会使美国受制于中国,反而将进一步巩固美国企业在全球医药领域的领先地位,并强化中国在药品供应环节对美国的依赖。2025年,美国对华医药贸易顺差达37亿美元。
10月下旬,美国财政部提议扩大《全面对外投资国家安全法案》的适用范围,该法案原旨在限制美国对中国战略敏感行业的投资,此次拟将生物技术产业整体纳入监管。此举将大幅限制美国企业投资、收购中国生物科技公司,或与其开展合作。
这种“一刀切”式的限制措施,更可能削弱美国自身实力,而非遏制中国。若美国企业被禁止与中国生物科技企业开展合作,中方企业并不会因此终止前景可观的研发项目。相反,它们将转而寻求与美国企业的国际竞争对手开展合作,或自主构建覆盖研发、生产及商业化环节的完整体系,从而摆脱对美合作伙伴的依赖。
长此以往,美国可能逐步丧失对下一代创新药物研发与供应链的掌控。患者等待前沿疗法的周期会拉长,参与临床试验的机会也会变少。
未来,美国获得创新药物更加依赖境外企业,恐构成严重国家安全隐患。
财政部官员明智的做法是收紧提案适用范围,只针对确实存在安全风险的生物技术交易——例如涉及生物武器技术的协议,而非一刀切地禁止常规科研合作。
财政部还需明确哪些合作模式属于禁令范畴。尽管提案本意允许常规授权许可协议,但条文表述宽泛,即便采用通用许可条款的合作,也有可能被认定为违规合资项目。这种政策不确定性,会迫使企业放弃有利的合作。
与此同时,政策制定者更应重视增强美国自身的科研实力:持续加大联邦科研投入、完善知识产权体系、保护科研机构免受外部干扰,并扩大本土研发与生产产能。
特朗普政府对中方发展目标保持警惕,但美国不能靠隔绝海外前沿科研成果,来维持自身在生物技术领域的领先地位。
唯有精准管控真正的安全风险,同时维护富有成效的研究伙伴关系,才能确保美国患者持续受益于全球最具潜力的医学突破。(财富中文网)
罗伊·布伦特1997年至2011年担任美国众议员,2011年至2023年出任参议员,曾任参议院情报特别委员会委员。他现任HB Strategies旗下领导力战略咨询服务集团主席,为制药和生物技术行业客户提供咨询,部分客户或受拟议中的《全面对外投资国家安全法案》相关规则影响。此外,他还担任Tenet Healthcare和Danforth Plant Science Center董事。
Fortune.com上发表的评论文章中表达的观点,仅代表作者本人的观点,不代表《财富》杂志的观点和立场。
译者:中慧言-王芳
During my 12 years in the U.S. Senate, I fought to ensure the United States dominated the global biotech industry. I did so not only because that leadership helps save American lives and drive economic growth, but also because it’s critical for our national security.
When American companies are second to none, we can respond quickly to public health emergencies without depending on foreign adversaries. I’ll always be proud that, in my role as chairman of the subcommittee overseeing the National Institutes of Health, I worked with colleagues in both parties to secure a nearly 50% increase in agency funding and accelerate research progress. That investment paid off during the Covid-19 pandemic, when President Trump’s Operation Warp Speed built on NIH initiatives to help end the pandemic and save countless American lives.
That’s why I’m worried about a well-intended, but counterproductive, new proposal from the Treasury Department that would restrict U.S. companies’ biotech investments in China.
It’s meant to enhance our national security by preventing American resources from building up China’s already growing biotech capabilities. Yet as written, the proposal is so broad that it could hurt American biotech companies far more than it hurts Chinese ones.
By hampering U.S. companies’ ability to develop breakthrough medicines as efficiently and quickly as possible, the proposal risks harming American patients and undermining our national security.
American drugmakers have often used acquisitions, joint ventures, and other partnerships to bring promising discoveries made abroad into our own research and development pipeline. As Chinese firms develop an increasing share of the world’s innovative drug candidates, these partnerships have only grown in their strategic importance.
These arrangements give American patients greater opportunities to participate in clinical trials and potentially gain access to lifesaving treatments. They also give American companies greater influence over how and where new medicines are developed and manufactured, helping secure reliable supplies.
Far from making America dependent on China, these partnerships keep American firms at the top of the global leaderboard, and ensure that China relies on the United States for medicines. In 2025, the United States recorded a $3.7 billion trade surplus with China in pharmaceuticals.
In late October, the Treasury Department proposed expanding the Comprehensive Outbound Investment National Security (COINS) Act, which limits U.S. investments in strategically sensitive Chinese industries, to cover the biotech sector writ large. That would broadly prevent U.S. companies from investing in, acquiring, or partnering with Chinese biotech firms.
Those broad restrictions are more likely to weaken the United States than China. If U.S. firms are functionally banned from partnering with Chinese biotechs, those Chinese firms won’t simply abandon their promising discoveries. Instead, they’ll seek to partner with American companies’ global rivals—or focus on building out their own research, manufacturing, and commercialization capabilities to replace the need for American partners.
Over time, America could lose influence over the development and supply of the next generation of innovative medicines. Patients could face longer waits for promising treatments and fewer opportunities to participate in clinical trials.
Our country could also become more reliant on foreign companies for access to future innovative drugs—a potentially serious national security vulnerability.
Treasury officials would be wise to narrow their proposal to focus on biotech deals that pose clear security threats—such as agreements involving technologies that could be used to produce biological weapons—without blocking ordinary research partnerships.
Treasury must also clearly define which arrangements are prohibited. Although the proposal is designed to allow standard licensing agreements, its broad language suggests that partnerships with common licensing terms could potentially be treated as prohibited joint ventures. That uncertainty could force companies to walk away from useful partnerships.
At the same time, policymakers should devote more attention to strengthening America’s own scientific capabilities. That means sustaining federal investment in scientific research, strengthening our intellectual property system, safeguarding our research institutions from foreign interference, and expanding domestic research and manufacturing capacity.
President Trump and his administration are right to be wary of China’s ambitions. But America can’t preserve its biotech lead by cutting itself off from promising advances made overseas.
By targeting genuine security threats while preserving beneficial research partnerships, we can strengthen America’s national security and ensure that American patients continue to benefit from the world’s most promising medical discoveries.
Roy Blunt served in the U.S. House of Representatives from 1997 to 2011 and in the U.S. Senate from 2011 to 2023, where he was a member of the Senate Select Committee on Intelligence. He chairs the Leadership Strategies Advisory Services group at HB Strategies, which advises clients in the pharmaceutical and biotech industries, including clients that would be affected by the proposed COINS rule. He also serves on the boards of Tenet Healthcare and the Danforth Plant Science Center.
The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune.